A5057845556- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Congenital Heart Disease Studies
- Cardiac pacing and defibrillation studies
- Cardiomyopathy and Myosin Studies
- Cardiac Structural Anomalies and Repair
- Vascular Procedures and Complications
- Angiogenesis and VEGF in Cancer
- Advanced X-ray and CT Imaging
- Mechanical Circulatory Support Devices
- Electroconvulsive Therapy Studies
- Acute Myocardial Infarction Research
- Cardiac Fibrosis and Remodeling
- Schizophrenia research and treatment
- Radiation Dose and Imaging
- Cardiovascular Issues in Pregnancy
- Health Systems, Economic Evaluations, Quality of Life
- Pain Management and Placebo Effect
- Aortic aneurysm repair treatments
- Cardiovascular Disease and Adiposity
- Cardiovascular Effects of Exercise
Karolinska University Hospital
2016-2025
Karolinska Institutet
2013-2024
Heart Foundation
2001-2024
Aarhus University Hospital
2005-2024
Helsinki University Hospital
2024
Copenhagen University Hospital
2024
Tampere University Hospital
2024
University of Copenhagen
2024
Skåne University Hospital
2024
Tampere University
2024
Transcatheter aortic valve implantation (TAVI) has become the first choice to treat older patients with severe symptomatic stenosis (AS). This study aimed compare TAVI surgery in low-risk ≤75 years of age, including both tricuspid and bicuspid AS.
The benefit of fractional flow reserve (FFR)-guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear.
BackgroundThe benefit of percutaneous coronary intervention (PCI) in patients with stable artery disease and severe aortic stenosis who are undergoing transcatheter aortic-valve implantation (TAVI) remains unclear.MethodsIn an international trial, we randomly assigned, a 1:1 ratio, symptomatic at least one coronary-artery fractional flow reserve 0.80 or less diameter 90% either to undergo PCI receive conservative treatment, all also TAVI. The primary end point was major adverse cardiac...
Transcatheter aortic valve implantation (TAVI), now a common procedure to treat high-risk patients with severe stenosis, has rapidly been expanding into younger and lower-risk populations, creating need better understand long-term outcome after TAVI. The aim of the present investigation was determine incidence, risk factors for, clinical presentation of, prosthetic endocarditis (PVE) in treated TAVI nationwide study.
This study was performed to investigate long-term, clinically important outcomes in patients who underwent permanent pacemaker implantation after transcatheter aortic valve replacement (TAVR).The impact of TAVR is unknown, and prior studies have produced conflicting results.In this nationwide, population-based cohort study, the included all transfemoral Sweden from 2008 2018 SWEDEHEART (Swedish Web-system for Enhancement Development Evidence-based care Heart disease Evaluated According...
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a treatment option for patients with severe tricuspid regurgitation (TR). However, randomized trials have not shown survival benefit, possibly because of the inclusion in an early or too advanced disease stage. The authors sought to investigate association between stage and outcomes following T-TEER. In total, 1,885 significant TR were analyzed, including 585 conservatively treated individuals 1,300 who received Patients...
For patients with severe aortic stenosis and coronary artery disease, the completely percutaneous approach to valve replacement revascularization has not been compared standard surgical approach.The prospective SURTAVI trial (Safety Efficiency Study of Medtronic CoreValve System in Treatment Severe, Symptomatic Aortic Stenosis Intermediate Risk Subjects Who Need Valve Replacement) enrolled intermediate-risk from 87 centers United States, Canada, Europe between June 2012 2016. Complex disease...
Aims:The aim of this study was to investigate whether minimising trauma the aortic annulus and left ventricular outflow tract reduces occurrence new conduction disorders need for permanent pacemakers.Methods results: A total 175 patients (58% female, mean age 83±6 years) underwent transfemoral TAVI with Boston Scientific ACURATE neo at three centres in Europe.Prosthesis size selection based on perimeter-derived annular diameter.Predilatation performed all a balloon 1.9±0.9mm smaller than...
Background— The aim of this substudy the EUROINJECT-ONE double-blind randomized trial was to analyze changes in myocardial perfusion NOGA-defined regions with intramyocardial injections plasmid encoding human (ph)VEGF-A 165 using an elaborated transformation algorithm. Methods and Results— After randomization, 80 no-option patients received either active, phVEGF-A (n=40), or placebo (n=40) percutaneously via NOGA-Myostar injections. injected area (region interest, ROI) delineated as a best...
To evaluate the feasibility of fully percutaneous closure using a novel collagen-based vascular device after transfemoral aortic valve replacement (TAVR).TAVR is utilized increasingly for treatment severe symptomatic stenosis. Vascular complications related to access and dominate adverse event profile procedure despite progressively reducing arteriotomy caliber. The advent (MANTATM ) preliminary data suggest this could be used as routine device.A prospective observational study unselected...
The next-generation ACURATE neo2 transcatheter aortic valve was designed for simplified implantation and to mitigate the risk of paravalvular leak (PVL) compared earlier device.
The ACURATE neo2 is a contemporary transcatheter aortic valve implantation (TAVI) system approved for the treatment of severe stenosis in Europe. has not been evaluated bicuspid (BAV) stenosis.
This NOTION-2 sub-study revealed distinct outcomes for transcatheter aortic valve replacement (TAVR) and surgical (SAVR) in low risk patients aged ≤ 70 years with a tricuspid or bicuspid stenosis (AS). One year after intervention, the of death, stroke rehospitalization AS was similar TAVR when compared to SAVR (absolute difference: -2.0%; 95% confidence interval (CI): -11.8% 7.7%) Conversely, AS, associated significantly higher adverse 13.8%; CI: 1.2% 26.3%). These analyses are exploratory,...
Abstract. Sarkar N, Rück A, Källner G, Y‐Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin L‐Å, Drvota V, Sylvén C (Karolinska Institute, Huddinge University Hospital, Novum, Stockholm, Sweden). Effects of intramyocardial injection phVEGF‐A 165 as sole therapy in patients with refractory coronary artery disease: 12‐month follow‐up. Angiogenic gene therapy. J Intern Med 2001; 250: 373–381. Objective. To test the safety and bioactivity after during Design....
1-year outcomes of 246 patients treated with the ACURATE neo2 valve for severe aortic stenosis, all-cause mortality 5.1% and no association found between HALT detected in 32.0% by CT clinical outcomes.
<h2>Abstract</h2><h3>Background</h3> ACUARTE neo2 (Neo2) implantation is performed after systematic Balloon Aortic Valvuloplasty (BAV) in most patients. No reports exist about the feasibility and safety of direct Neo2 transcatheter aortic valve (TAVI) comparison to standard practice. <h3>Aim</h3> We aimed identify patients' baseline anatomical characteristics, procedural, early post-procedural outcomes patients treated using with without BAV. <h3>Methodology</h3> This a retrospective...
The aim of this study was to assess the performance a self-expanding valve in bicuspid aortic (BAV) stenosis.An international registry included total 712 patients with stenosis treated ACURATE neo (n=54; 7.5%) or tricuspid (n=658; 92.4%) anatomy. overall mean age 81±5.6 years. At baseline, no significant differences were found between two groups. BAV more frequently required both predilatation (94.4% vs. 78.1%, p=0.004) and post-dilation (57.4% 38.7%, p=0.007). Moderate perivalvular...